Cargando…

Real-world use of ceftolozane/tazobactam: a systematic literature review

BACKGROUND: Antibacterial-resistant gram-negative infections are a serious risk to global public health. Resistant Enterobacterales and Pseudomonas aeruginosa are highly prevalent, particularly in healthcare settings, and there are limited effective treatment options. Patients with infections caused...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puzniak, Laura, Dillon, Ryan, Palmer, Thomas, Collings, Hannah, Enstone, Ashley
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027296/ https://www.ncbi.nlm.nih.gov/pubmed/33832545 http://dx.doi.org/10.1186/s13756-021-00933-8

Ejemplares similares

Systematic Literature Review of Real-world Evidence of Ceftolozane/Tazobactam for the Treatment of Respiratory Infections
por: Puzniak, Laura, et al.
Publicado: (2021)

Ceftolozane/tazobactam for the treatment of bacteremia: a systematic literature review (SLR)
por: Khankhel, Z. S., et al.
Publicado: (2022)

1596. Ceftolozane/tazobactam (Zerbaxa) for the Treatment of Pseudomonas aeruginosa (PSA) Bacteremia: A Systematic Literature Review (SLR)
por: Dillon, Ryan J, et al.
Publicado: (2020)

2248. Clinical and Microbiological Outcomes Associated with Real-World Use of Ceftolozane/Tazobactam
por: Cabrera, Nicolo, et al.
Publicado: (2019)

1612. Evaluation of the Use of Ceftolozane/Tazobactam for the Treatment of ESBL-producing Enterobacterales Infections Using International Data from SPECTRA (Study of Prescribing Patterns and Effectiveness of Ceftolozane/Tazobactam Real World Analysis)
por: Soriano, Alex, et al.
Publicado: (2020)

2414. Real-World Evaluation of Patient Characteristics and Outcomes of Patients Treated With Ceftolozane/Tazobactam Across 253 US Hospitals
por: Puzniak, Laura, et al.
Publicado: (2018)

Real-world Evaluation of Ceftolozane/Tazobactam (C/T) Use and Clinical Outcomes at an Academic Medical Center in Las Vegas
por: Leuthner, Kimberly D, et al.
Publicado: (2017)

A Real-world Multicenter Outpatient Experience of Ceftolozane/Tazobactam
por: Van Anglen, Lucinda J, et al.
Publicado: (2023)

Healthcare Resource Utilization of Ceftolozane/Tazobactam Versus Meropenem for Ventilated Nosocomial Pneumonia from the Randomized, Controlled, Double-Blind ASPECT-NP Trial
por: Lodise, Thomas, et al.
Publicado: (2020)

Real-world Analysis of Prescribing Patterns and Susceptibility of Ceftolozane/Tazobactam (C/T) Treatment using an Electronic Medical Record (EMR) Database in the United States
por: Pogue, Jason M, et al.
Publicado: (2017)

Ceftolozane/Tazobactam for Resistant Drugs Pseudomonas aeruginosa Respiratory Infections: A Systematic Literature Review of the Real-World Evidence
por: Giaccari, Luca Gregorio, et al.
Publicado: (2021)

2200. Cost-effectiveness of Ceftolozane/Tazobactam for Treating Ventilated Nosocomial Bacterial Pneumonia
por: Naik, Jaesh, et al.
Publicado: (2019)

Cost Effectiveness of Ceftolozane/Tazobactam Compared with Meropenem for the Treatment of Patients with Ventilated Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
por: Naik, Jaesh, et al.
Publicado: (2021)

2279. Study of Prescribing patterns and Effectiveness of Ceftolozane–tazobactam (C/T): Real-world Analysis (SPECTRA): a multi-national, multicenter observational study
por: Soriano, Alex, et al.
Publicado: (2019)

Ceftolozane-Tazobactam Combination Therapy Compared to Ceftolozane-Tazobactam Monotherapy for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis
por: Fiore, Marco, et al.
Publicado: (2021)

Ceftolozane-tazobactam in nosocomial pneumonia
por: Candel, Francisco Javier, et al.
Publicado: (2022)

The Comparative Effectiveness of Ceftolozane/Tazobactam versus Aminoglycoside- or Polymyxin-Based Regimens in Multi-Drug-Resistant Pseudomonas aeruginosa Infections
por: Caffrey, Aisling R., et al.
Publicado: (2022)

2291. Evaluation of Multidrug-Resistant Pseudomonas aeruginosa Isolates in Patients Receiving Ceftolozane/tazobactam
por: Bodo, Emily C, et al.
Publicado: (2019)

1625. Real-World Outpatient Utilization of Ceftolozane/Tazobactam in Physician Office Infusion Centers (OICs)
por: Van Anglen, Lucinda J, et al.
Publicado: (2020)

Erratum: Ceftolozane-tazobactam in nosocomial pneumonia
por: FJ, Candel, et al.
Publicado: (2022)

A Multicenter Evaluation of Ceftolozane/Tazobactam Treatment Outcomes in Immunocompromised Patients With Multidrug-Resistant Pseudomonas aeruginosa Infections
por: Hart, Delaney E, et al.
Publicado: (2021)

Ceftolozane-tazobactam: When, how and why using it?
por: López, Inmaculada, et al.
Publicado: (2021)

1282. Ceftolozane/Tazobactam Use in Critically Ill Patients Receiving Intermittent or Continuous Renal Replacement Therapy
por: Henry, Molly, et al.
Publicado: (2021)

1319. Pharmacokinetics of Ceftolozane/Tazobactam in Patients with Burns
por: Hall, Ronald G, et al.
Publicado: (2020)

2281. Ceftolozane–tazobactam (C/T) Treatment Outcomes in Immunocompromised (IC) Patients with Multidrug-Resistant (MDR) Pseudomonas aeruginosa (PA) Infections
por: Hart, Delaney E, et al.
Publicado: (2019)

1608. Efficacy of Ceftolozane/Tazobactam for Multidrug-Resistant Gram-Negative Infections in Multiple Urban Hospitals
por: Cabrera, Nicolo, et al.
Publicado: (2020)

Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa
por: Barnes, Melissa D., et al.
Publicado: (2018)

Chemical Stability of Ceftolozane/Tazobactam in Polyvinylchloride Bags and Elastomeric Pumps
por: Terracciano, Joseph, et al.
Publicado: (2017)

Ceftolozane/Tazobactam Dosing Requirements Against Pseudomonas aeruginosa Bacteremia
por: Ruiz, Jesus, et al.
Publicado: (2020)

Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa
por: Teo, Jocelyn Qi-Min, et al.
Publicado: (2021)

Ceftolozane–tazobactam- and ceftazidime–avibactam-resistant Pseudomonas aeruginosa mastoiditis
por: Jacobs, Jeremy, et al.
Publicado: (2020)

Comparison between meropenem and ceftolozane/tazobactam: possible influence of CRRT
por: Honore, Patrick M., et al.
Publicado: (2022)

Clinical characteristics, microbiology and outcomes of a cohort of patients treated with ceftolozane/tazobactam in acute care inpatient facilities, Houston, Texas, USA
por: Tran, Truc T, et al.
Publicado: (2023)

Use of Ceftolozane/Tazobactam in a Case of Septic Shock by Puerperal Sepsis
por: Pezzi, Mario, et al.
Publicado: (2019)

In Vitro Activity of Ceftolozane/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates
por: Forrester, Jeanne B, et al.
Publicado: (2018)

Ceftolozane–tazobactam for the treatment of osteomyelitis caused by multidrug-resistant pathogens: a case series
por: Tan, Xing, et al.
Publicado: (2019)

Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
por: Goodlet, Kellie J, et al.
Publicado: (2016)

Failure of ceftolozane‐tazobactam salvage therapy in complicated pneumonia with lung abscess
por: Lewis, Paul O., et al.
Publicado: (2018)

Clinical and Safety Evaluation of Continuously Infused Ceftolozane/Tazobactam in the Outpatient Setting
por: Jones, Bruce M, et al.
Publicado: (2020)

Ceftolozane/tazobactam heteroresistance in cystic fibrosis-related Pseudomonas aeruginosa infections
por: Monogue, Marguerite L, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l1g7jd1pt266pknk116d65o2kd